CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates

References

• Swerdlow SH, Campo E, Harris NL, et al. The WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008.
   Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655–2663.
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L + T cells by producing CCL22. Eur J Immunol 2002; 32: 1403–1413.
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387–2396.
   PubMed Web of Science ®Google Scholar
• Os A, Burgler S, Ribes AP, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep 2013; 4: 566–577.
   PubMed Web of Science ®Google Scholar
• Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008; 111: 5173–5181.
   PubMed Web of Science ®Google Scholar
• Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014; 24: 71–81.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Katz BZ, Lipsky A, et al. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013; 27: 173–206.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563–574.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15: 1090–1099.
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050–3058.
   PubMed Web of Science ®Google Scholar
• Schall TJ, Bacon K, Camp RD, et al. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821–1826.
   PubMed Web of Science ®Google Scholar
• Taub DD, Lloyd AR, Wang JM, et al. The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol 1993; 351: 139–146.
   PubMedGoogle Scholar
• Tregoning JS, Pribul PK, Pennycook AM, et al. The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One 2010; 5: e9381.
   PubMed Web of Science ®Google Scholar
• Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 1662–1669.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497–4503.
   PubMed Web of Science ®Google Scholar
• Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010; 95: 1526–1533.
   PubMed Web of Science ®Google Scholar
• Brighenti A, Andrulis M, Geissinger E, et al. Extrafollicular proliferation of B cells in the absence of follicular hyperplasia: a distinct reaction pattern in lymph nodes correlated with primary or recall type responses. Histopathology 2005; 47: 90–100.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765–772.
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350–354.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492–499.
   PubMed Web of Science ®Google Scholar
• Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 2015; 16: 142–152.
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 802–810.
   PubMed Web of Science ®Google Scholar
• Xerri L, Chetaille B, Serriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 39: 1050–1058.
   PubMed Web of Science ®Google Scholar
• Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007; 92: 1059–1066.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182–1189.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603–3612.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805–812.
   PubMed Web of Science ®Google Scholar
• Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011; 117: 5463–5472.
   PubMed Web of Science ®Google Scholar
• Goolsby CL, Kuchnio M, Finn WG, et al. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 2000; 42: 188–195.
   PubMedGoogle Scholar
• Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997; 158: 1482–1489.
   PubMed Web of Science ®Google Scholar
• Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011; 134: 17–32.
   PubMed Web of Science ®Google Scholar
• Kim JR, Lim HW, Kang SG, et al. Human CD57+ germinal center-T cells are the major helpers for GC-B cells and induce class switch recombination. BMC Immunol 2005; 6: 3.
   PubMed Web of Science ®Google Scholar
• Bandres E, Merino J, Vazquez B, et al. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol 2000; 96: 230–235.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhong W, Lu X, et al. Association of Graves’ disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells. J Clin Immunol 2008; 28: 464–472.
   PubMed Web of Science ®Google Scholar
• Eylar EH, Lefranc CE, Yamamura Y, et al. HIV infection and aging: enhanced interferon- and tumor necrosis factor-alpha production by the CD8+ CD28- T subset. BMC Immunol 2001; 2: 10.
   PubMedGoogle Scholar
• Buschle M, Campana D, Carding SR, et al. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213–218.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Dmoszynska A, Rolinski J. Intracellular IFN-gamma expression by CD3+/CD8+ cell subset in B-CLL patients correlates with stage of the disease. Eur J Haematol 2004; 73: 29–35.
   PubMed Web of Science ®Google Scholar
• Bürgler S, Gimeno A, Parente-Ribes A, et al. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-gamma by a T-bet-dependent mechanism. J Immunol 2015; 194: 827–835.
   PubMed Web of Science ®Google Scholar
• Chaput N, Svrcek M, Auperin A, et al. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer 2013; 109: 1013–1022.
   PubMed Web of Science ®Google Scholar
• Iida M, Takayama E, Naganawa K, et al. Increase of peripheral blood CD57+ T-cells in patients with oral squamous cell carcinoma. Anticancer Res 2014; 34: 5729–5734.
   PubMed Web of Science ®Google Scholar
• Akagi J, Baba H. Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer. Int J Clin Oncol 2008; 13: 528–535.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350–5357.
   PubMed Web of Science ®Google Scholar
• Focosi D, Petrini M. CD57 expression on lymphoma microenvironment as a new prognostic marker related to immune dysfunction. J Clin Oncol 2007; 25: 1289–12891; author reply 91–92.
   PubMed Web of Science ®Google Scholar